Suzuken
Pharmaceutical company that manufactures and markets ethical drugs.
Launch date
Employees
Market cap
AUD4.7b
Enterprise valuation
AUD1.8b (Public information from Sep 2024)
Share price
JPY5021 9987.T
Japan (HQ)
Financials
Estimates*
| JPY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.1t | 2.2t | 2.3t | 2.4t | 2.4t | 2.4t | 2.5t |
| % growth | (4 %) | 5 % | 4 % | 3 % | 1 % | 2 % | 1 % |
| EBITDA | 28.5b | 33.0b | 45.1b | 47.0b | 40.3b | 42.4b | 43.0b |
| % EBITDA margin | 1 % | 1 % | 2 % | 2 % | 2 % | 2 % | 2 % |
| Profit | 7.9b | 14.4b | 20.3b | 29.0b | 26.5b | 22.4b | 23.0b |
| % profit margin | - | 1 % | 1 % | 1 % | 1 % | 1 % | 1 % |
| EV / revenue | 0.1x | 0.1x | 0.0x | 0.1x | 0.2x | 0.2x | 0.2x |
| EV / EBITDA | 6.1x | 3.6x | 1.9x | 2.5x | 9.9x | 9.4x | 9.3x |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Suzuken
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
